Year |
Citation |
Score |
2020 |
Agurto C, Cecchi GA, Norel R, Ostrand R, Kirkpatrick M, Baggott MJ, Wardle MC, Wit H, Bedi G. Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31978933 DOI: 10.1038/S41386-020-0620-4 |
0.558 |
|
2019 |
Baggott MJ, Garrison KJ, Coyle JR, Galloway GP, Barnes AJ, Huestis MA, Mendelson JE. Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. Journal of Psychoactive Drugs. 1-10. PMID 30967099 DOI: 10.1080/02791072.2019.1593560 |
0.394 |
|
2016 |
Bershad AK, Miller MA, Baggott MJ, de Wit H. The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? Journal of Psychopharmacology (Oxford, England). PMID 27562198 DOI: 10.1177/0269881116663120 |
0.679 |
|
2016 |
Baggott MJ, Garrison KJ, Coyle JR, Galloway GP, Barnes AJ, Huestis MA, Mendelson JE. MDMA Impairs Response to Water Intake in Healthy Volunteers. Advances in Pharmacological Sciences. 2016: 2175896. PMID 27403159 DOI: 10.1155/2016/2175896 |
0.349 |
|
2016 |
Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway G, Mendelson JE. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. Journal of Psychopharmacology (Oxford, England). PMID 26880224 DOI: 10.1177/0269881115626348 |
0.387 |
|
2015 |
Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H. Intimate insight: MDMA changes how people talk about significant others. Journal of Psychopharmacology (Oxford, England). 29: 669-77. PMID 25922420 DOI: 10.1177/0269881115581962 |
0.614 |
|
2014 |
Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME, Hysek CM, de Wit H. MDMA effects consistent across laboratories. Psychopharmacology. 231: 3899-905. PMID 24633447 DOI: 10.1007/S00213-014-3528-Z |
0.549 |
|
2013 |
Weafer J, Baggott MJ, de Wit H. Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention. Experimental and Clinical Psychopharmacology. 21: 475-81. PMID 24099351 DOI: 10.1037/A0033659 |
0.443 |
|
2013 |
Pal R, Balt S, Erowid E, Erowid F, Baggott MJ, Mendelson J, Galloway GP. Ketamine is associated with lower urinary tract signs and symptoms. Drug and Alcohol Dependence. 132: 189-94. PMID 23474358 DOI: 10.1016/J.Drugalcdep.2013.02.005 |
0.339 |
|
2013 |
Baggott MJ, Childs E, Hart AB, de Bruin E, Palmer AA, Wilkinson JE, de Wit H. Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology. 228: 109-18. PMID 23420115 DOI: 10.1007/S00213-013-3021-0 |
0.524 |
|
2011 |
Mendelson J, Baggott MJ, Flower K, Galloway G. Developing biomarkers for methamphetamine addiction. Current Neuropharmacology. 9: 100-3. PMID 21886571 DOI: 10.2174/157015911795017128 |
0.332 |
|
2011 |
Li L, Galloway GP, Verotta D, Everhart ET, Baggott MJ, Coyle JR, Lopez JC, Mendelson J. A method to quantify illicit intake of drugs from urine: methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 338: 31-6. PMID 21450932 DOI: 10.1124/Jpet.111.179176 |
0.346 |
|
2011 |
Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Baggott MJ, Li L, Polcin D, Chen CY, Mendelson J. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clinical Pharmacology and Therapeutics. 89: 276-82. PMID 21178989 DOI: 10.1038/Clpt.2010.307 |
0.326 |
|
2011 |
Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology. 214: 933-9. PMID 21140258 DOI: 10.1007/S00213-010-2103-5 |
0.396 |
|
2011 |
Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug and Alcohol Dependence. 114: 61-7. PMID 21035275 DOI: 10.1016/J.Drugalcdep.2010.09.006 |
0.519 |
|
2010 |
Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. Plos One. 5: e14074. PMID 21152030 DOI: 10.1371/Journal.Pone.0014074 |
0.567 |
|
2010 |
Galloway GP, Singleton EG, Buscemi R, Baggott MJ, Dickerhoof RM, Mendelson JE. An examination of drug craving over time in abstinent methamphetamine users. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 19: 510-4. PMID 20958846 DOI: 10.1111/J.1521-0391.2010.00082.X |
0.337 |
|
2010 |
Flower K, Li L, Chen CY, Baggott MJ, Galloway GP, Mendelson J. Efficacy, safety, and ethics of cosmetic neurology far from settled. Clinical Pharmacology and Therapeutics. 88: 461-3. PMID 20856245 DOI: 10.1038/Clpt.2010.194 |
0.355 |
|
2010 |
Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J. Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug and Alcohol Dependence. 111: 250-6. PMID 20627425 DOI: 10.1016/J.Drugalcdep.2010.05.003 |
0.41 |
|
2010 |
Li L, Lopez JC, Galloway GP, Baggott MJ, Everhart T, Mendelson J. Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Therapeutic Drug Monitoring. 32: 504-7. PMID 20592647 DOI: 10.1097/Ftd.0B013E3181Db82F2 |
0.363 |
|
2004 |
Baggott MJ, Erowid E, Erowid F, Mendelson JE. Use of salvia divinorum, an unscheduled hallucinogenic plant: a web‐based survey of 500 users Clinical Pharmacology & Therapeutics. 75: 72. DOI: 10.1016/J.Clpt.2003.11.270 |
0.332 |
|
2002 |
Baggott MJ. Preventing problems in Ecstasy users: reduce use to reduce harm. Journal of Psychoactive Drugs. 34: 145-62. PMID 12691205 DOI: 10.1080/02791072.2002.10399949 |
0.311 |
|
2002 |
Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 162: 396-405. PMID 12172693 DOI: 10.1007/S00213-002-1131-1 |
0.571 |
|
2001 |
Vollenweider FX, Jones RT, Baggott MJ. Caveat emptor: editors beware. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 461-3. PMID 11310414 DOI: 10.1016/S0893-133X(00)00170-6 |
0.396 |
|
2000 |
Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Annals of Internal Medicine. 133: 969-73. PMID 11119398 DOI: 10.7326/0003-4819-133-12-200012190-00012 |
0.491 |
|
2000 |
Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. Jama. 284: 2190. PMID 11056589 DOI: 10.1001/Jama.284.17.2190 |
0.411 |
|
1999 |
Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology. 141: 37-46. PMID 9952063 DOI: 10.1007/S002130050804 |
0.516 |
|
1997 |
Jacob P, Mendelson J, Everhart ET, Nath R, Baggott M, Welm S, Jones RT. Formation and elimination of cocaethylene in humans Clinical Pharmacology and Therapeutics. 61: 222. |
0.345 |
|
1996 |
Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical Pharmacology and Therapeutics. 60: 105-14. PMID 8689806 DOI: 10.1016/S0009-9236(96)90173-3 |
0.527 |
|
1993 |
Richards JB, Baggott MJ, Sabol KE, Seiden LS. A high-dose methamphetamine regimen results in long-lasting deficits on performance of a reaction-time task. Brain Research. 627: 254-60. PMID 8298969 DOI: 10.1016/0006-8993(93)90328-K |
0.471 |
|
Show low-probability matches. |